Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.61 0.87 (0.99%) as of 4:30 Wed 3/27


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.69(B)
Last Volume: 1,031,697 Avg Vol: 1,398,626
52 Week Range: $76.22 - $100.3
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:

    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 92,341 116,105 269,465 610,463
Total Sell Value $8,237,699 $10,489,308 $24,880,826 $57,517,351
Total People Sold 3 4 5 8
Total Sell Transactions 9 11 22 59
End Date 2023-12-28 2023-09-26 2023-03-28 2022-03-28

   
Records found: 1303
  Page 7 of 53  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2013-11-01 4 AS $63.16 $6,253 D/D (99) 14,880     -
   Baffi Robert EVP, Technical Operations   •       –      –    2013-10-31 5 A $27.91 $2,567 D/D 92 60,422     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-10-31 5 A $55.44 $4,047 D/D 73 38,023     -
   Davis George Eric SVP, Chief Commercial Of   •       –      –    2013-10-31 5 A $27.91 $1,339 D/D 48 50,156     -
   Mueller Brian VP, Corporate Controller   •       –      –    2013-10-31 5 A $27.91 $7,758 D/D 278 8,725     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2013-10-31 4 A $27.91 $2,763 D/D 99 14,979     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-10-31 4 AS $62.72 $627,155 I/I (10,000) 45,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-10-31 4 OE $12.99 $129,900 I/I 10,000 55,740     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-10-30 4 A $65.75 $595 D/D 9 68,752     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-10-16 4 AS $67.73 $135,450 I/I (2,000) 45,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-10-16 4 OE $12.99 $25,980 I/I 2,000 47,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-10-10 4 AS $66.76 $200,291 I/I (3,000) 45,740     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-10-07 4 A $74.84 $449 D/D 6 68,743     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-10-04 4 A $74.07 $370 D/D 5 68,737     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-09-19 4 AS $80.19 $801,900 D/D (10,000) 43,266     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-09-19 4 OE $11.05 $110,500 D/D 10,000 53,266     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-09-16 4 AS $73.08 $146,163 I/I (2,000) 48,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-09-16 4 OE $12.99 $25,980 I/I 2,000 50,740     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-09-10 4 A $70.06 $1,053 D/D 15 68,732     -
   Baffi Robert EVP, Technical Operations   •       –      –    2013-09-09 4 AS $73.00 $1,460,000 D/D (20,000) 62,262     -
   Baffi Robert EVP, Technical Operations   •       –      –    2013-09-09 4 OE $21.51 $430,200 D/D 20,000 82,262     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-09-05 4 AS $70.00 $700,000 D/D (10,000) 43,266     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-09-05 4 OE $11.05 $110,500 D/D 10,000 53,266     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-09-04 4 AS $69.00 $621,000 D/D (9,000) 37,950     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-09-04 4 OE $39.06 $351,540 D/D 9,000 46,950     -

  1303 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 7 of 53
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed